Zou, Xinliang
Liao, Yi
Liu, Zhihui
Xu, Xiang
Sun, Weiwei
Qin, Haoran
Wang, Haidong
Liu, Jianping
Jing, Tao http://orcid.org/0000-0002-1187-4534
Funding for this research was provided by:
National Natural Sciences Foundation of China (81370212)
Special Project for Enhancing Science and Technology Innovation Ability (frontier exploration) of Army Medical University (2019XQY13)
Promotion for Appropriate Technology in Health, Project: Standardized Diagnosis and Treatment of Coronary Atherosclerotic Heart Disease (2018jstg036)
Article History
Received: 9 January 2022
Accepted: 12 July 2022
First Online: 28 July 2022
Change Date: 24 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12265-022-10308-y
Declarations
:
: In this study, all animal experiments were approved by the Committee on the Use and Care on Animals (The Army Medical University, Chongqing, China) and performed in accordance with institution guidelines. Consent to participate is not applicable.
: Not applicable.
: The authors declare no competing interests.
: At present, the biggest obstacle of BMSCs implantation for treatment of arterial injury is the low survival rate and high differentiation rate of BMSCs after transplantation. Also, the potential teratogenic and tumorigenic risks also significantly limit its clinical application. This study innovatively created AT2R gene-modified BMSCs exosomes (AT2R-EXO). By intravenous injection, AT2R-EXO could directionally home and aggregate to the target vascular injured area, and inhibit the formation of the neointimal hyperplasia. AT2R-EXO not only has better efficacy than EXO, but also reduces the risk of BMSCs transplantation. The findings provide new strategies for treatment of restenosis diseases after intervention.